secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001140361-25-017958
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma Q1 net loss $61.3M; cash $318.2M; pipeline on track
-----------------------------------------------------------------

- Net loss of $61.3M ($0.56/share) vs $62.1M in Q1 2024; R&D expenses down to $35.9M.
- Cash, equivalents, investments $318.2M; operational runway into Q4 2026.
- Phase 2 RP-A501 for Danon disease ongoing; program update mid-2025, data mid-2026.
- Initial Phase 1 data for RP-A601 (PKP2-ACM) expected May 2025; IND for BAG3-DCM mid-2025.
- Rolling BLA for RP-L102 (Fanconi Anemia); final module late 2025/early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/0001140361-25-017958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125017958/ef20048651_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-017958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer